Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 03 2022
18 03 2022
Historique:
received:
13
10
2021
accepted:
10
03
2022
entrez:
19
3
2022
pubmed:
20
3
2022
medline:
6
5
2022
Statut:
epublish
Résumé
To compare the anatomical/functional changes after navigated subthreshold pulse laser (SML) and oral eplerenone therapy for chronic central serous chorioretinopathy (cCSC). A total of 36 eyes of 36 patients suffering from cCSC treated with navigated SML (Navilas® 577s; OD-OS GmbH, near Berlin, Germany) (18 eyes, SML group) and oral eplerenone (18 eyes, eplerenone group) were enrolled in this retrospective study. Main outcome measures during a 3-month follow up period included changes of best corrected visual acuity (BCVA), central macular thickness (CMT), foveal subretinal fluid thickness (FSRFT), and subfoveal choroidal thickness (SFCT). At baseline average duration of symptoms was 6.8 ± 0.6 months in SML group and 6.4 ± 0.9 months in eplerenone group (p = 0.127). Mean BCVA, CMT and FSRFT changed significantly over time (p < 0.001). From baseline to 90 days the BCVA improved from 0.3 ± 0.1 to 0.1 ± 0.1 logMAR in SML group and from 0.3 ± 0. to 0.2 ± 0.1 logMAR in eplerenone group, CMT reduced from 357.1 ± 104.3 to 210.6 ± 46.7 μm and from 428.7 ± 107.7 to 332.5 ± 27.5 μm in SML group and eplerenone group respectively, FSRFT reduced from 144.4 ± 108.2 to 22.6 ± 37.2 μm and from 217.1 ± 105.9 to 54.4 ± 86.2 μm in SML group and eplerenone group. 55.6% of patients in SML group and 66.7% in eplerenone group showed a complete resolution of FSRFT during follow up. The interaction between group and time was statistically significant with greater absolute variation for CMT and FSRFT in SML group compared to eplerenone group (p < 0.001 and p = 0.043). SFCT did not change significantly during follow up (p = 0.083) for both groups. Both navigated SML and oral eplerenone were effective treatments showing recovery of retinal morphology and related visual acuity improvement in cCSC.
Identifiants
pubmed: 35304566
doi: 10.1038/s41598-022-08764-2
pii: 10.1038/s41598-022-08764-2
pmc: PMC8933552
doi:
Substances chimiques
Eplerenone
6995V82D0B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4727Informations de copyright
© 2022. The Author(s).
Références
Liew, G., Quin, G., Gillies, M. & Fraser-Bell, S. Central serous chorioretinopathy: A review of epidemiology and pathophysiology. Clin. Exp. Ophthalmol. 41, 201–214 (2013).
pubmed: 22788735
doi: 10.1111/j.1442-9071.2012.02848.x
Cheung, C. M. G. et al. Pachychoroid disease. Eye 33, 14–33 (2019).
pubmed: 29995841
doi: 10.1038/s41433-018-0158-4
Loo, R. H. et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22, 19–24 (2002).
pubmed: 11884873
doi: 10.1097/00006982-200202000-00004
Fok, A. C. T., Chan, P. P. M., Lam, D. S. C. & Lai, T. Y. Y. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res. 46, 160–163 (2011).
pubmed: 21389741
doi: 10.1159/000324599
Kitzmann, A. S., Pulido, J. S., Diehl, N. N., Hodge, D. O. & Burke, J. P. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 115, 169–173 (2008).
pubmed: 18166410
doi: 10.1016/j.ophtha.2007.02.032
Kim, Y. J. et al. Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years. Eye 33, 819–825 (2019).
pubmed: 30610228
pmcid: 6707150
doi: 10.1038/s41433-018-0309-7
Chan, W. M., Lai, T. Y. Y., Lai, R. Y. K., Liu, D. T. L. & Lam, D. S. C. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy. One-year results of a randomized controlled trial. Ophthalmology 115, 1756–1765 (2008).
pubmed: 18538401
doi: 10.1016/j.ophtha.2008.04.014
Zhao, M. W. et al. Photodynamic therapy for acute central serous chorioretinopathy: The safe effective lowest dose of verteporfin. Retina 29, 1155–1161 (2009).
pubmed: 19629018
doi: 10.1097/IAE.0b013e3181a6c028
Khosla, P. K., Rana, S. S., Tewari, H. K., Azad, R. U. & Talwar, D. Evaluation of visual function following argon laser photocoagulation in central serous retinopathy. Ophthalmic Surg. Lasers 28, 693–697 (1997).
pubmed: 9269005
doi: 10.3928/1542-8877-19970801-16
Schatz, H., Yannuzzi, L. A. & Gitter, K. A. Subretinal neovascularization following argon laser photocoagulation treatment for central serous chorioretinopathy. Retina 32, OP-893-OP-906 (2012).
doi: 10.1097/IAE.0b013e318242fa2d
Lotery, A. et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): A randomised, double-blind, placebo-controlled trial. Lancet 395(10220), 294–303 (2020).
pubmed: 31982075
doi: 10.1016/S0140-6736(19)32981-2
Salehi, M., Wenick, A. S., Law, H. A., Evans, J. R. & Gehlbach P. Interventions for central serous chorioretinopathy: A network meta-analysis. Cochrane Database Syst. Rev. CD011841 (2015).
Elhamid, A. H. A. Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy. Clin. Ophthalmol. 9, 2277–2283 (2015).
Özmert, E., Demirel, S., Yanık, O. & Batıoğlu, F. Low-fluence photodynamic therapy versus subthreshold micropulse yellow wavelength laser in the treatment of chronic central serous chorioretinopathy. J. Ophthalmol. 2016, 3513794 (2016).
pubmed: 27597894
pmcid: 5002482
Scholz, P., Altay, L. & Fauser, S. A review of subthreshold micropulse laser for treatment of macular disorders. Adv. Ther. 34, 1528–1555 (2017).
pubmed: 28540655
pmcid: 5504253
doi: 10.1007/s12325-017-0559-y
Zhou, L. et al. A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy. Lasers Med. Sci. 34, 1345–1351 (2019).
pubmed: 30710172
doi: 10.1007/s10103-019-02721-8
Sivaprasad, S., Elagouz, M., McHugh, D., Shona, O. & Dorin, G. Micropulsed diode laser therapy: evolution and clinical applications. Surv. Ophthalmol. 2010(55), 516–530. https://doi.org/10.1016/j.survophthal.2010.02.005 (2010).
doi: 10.1016/j.survophthal.2010.02.005
Vignesh, T. P. et al. Subthreshold micro-pulse yellow laser and eplerenone drug therapy in chronic central serous chorio-retinopathy patients: A comparative study. Semin. Ophthalmol. 35, 237–245 (2020).
pubmed: 32853034
doi: 10.1080/08820538.2020.1809682
Luttrull, J. K. & Dorin, G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: A review. Curr. Diabetes Rev. 8, 274–284 (2012).
pubmed: 22587512
pmcid: 3412206
doi: 10.2174/157339912800840523
Inagaki, K. et al. Sublethal photothermal stimulation with a micropulse laser induces heat shock protein expression in ARPE-19 cells. J. Ophthalmol. 2015, 729792 (2015).
pubmed: 26697211
pmcid: 4677213
Kato, F. et al. Evaluation of navigated laser photocoagulation (Navilas 577+) for the treatment of refractory diabetic macular edema. J. Ophthalmol. 2018(3978514), 2018. https://doi.org/10.1155/2018/3978514.eCollection (2018).
doi: 10.1155/2018/3978514.eCollection
Yadav, N. K., Jayadev, C., Rajendran, A. & Nagpal, M. Recent developments in retinal lasers and delivery systems. Indian J. Ophthalmol. 62, 50–54 (2014).
pubmed: 24492501
pmcid: 3955070
doi: 10.4103/0301-4738.126179
Müller, B., Tatsios, J., Klonner, J., Pilger, D. & Joussen, A. M. Navigated laser photocoagulation in patients with non-resolving and chronic central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 256, 1581–1588 (2018).
pubmed: 29876733
doi: 10.1007/s00417-018-4031-8
Kernt, M. et al. Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas®). Clin. Ophthalmol. 6, 289 (2012).
pubmed: 22393280
pmcid: 3292412
doi: 10.2147/OPTH.S27859
Bandello, F., Lanzetta, P., Furlan, F. & Polito, A. Nonvisible subthreshold MicroPulse diode laser treatment of idiopathic central serous chorioretinopathy: A pilot study. Eur. J. Ophthalmol. 44, 934–940 (2008).
Gupta, B., Elagouz, M., McHugh, D., Chong, V. & Sivaprasad, S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clin. Exp. Ophthalmol. 37, 801–805 (2009).
pubmed: 19878226
doi: 10.1111/j.1442-9071.2009.02157.x
Malik, K. J., Sampat, K. M., Mansouri, A., Steiner, J. N. & Glaser, B. M. Low-intensity/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy. Retina 35, 532–536 (2015).
pubmed: 25127050
doi: 10.1097/IAE.0000000000000285
Kim, J. Y., Park, H. S. & Kim, S. Y. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 253, 2129–2135 (2015).
pubmed: 25717024
doi: 10.1007/s00417-015-2965-7
Luttrull, J. K. Low-intensity/high-density subthreshold diode micropulse laser for central serous chorioretinopathy. Retina 36, 1658–1663 (2016).
pubmed: 27206160
doi: 10.1097/IAE.0000000000001005
Iacono, P., Battaglia Parodi, M., Falcomatà, B. & Bandello, F. Central serous chorioretinopathy treatments: a mini review. Ophthalmic Res. 55, 76–83 (2015).
pubmed: 26619293
doi: 10.1159/000441502
Scholz, P., Ersoy, L., Boon, C. J. & Fauser, S. Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy. Ophthalmologica 234, 189–194 (2015).
pubmed: 26406874
doi: 10.1159/000439600
Gawecki, M., Jaszczuk-Maciejewska, A., Jurska-Jaśko, A. & Grzybowski, A. Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser. Graefes Arch. Clin. Exp. Ophthalmol. 255, 2299–2306 (2017).
pubmed: 28831603
pmcid: 5696495
doi: 10.1007/s00417-017-3783-x
Maruko, I., Koizumi, H., Hasegawa, T., Arakawa, H. & Iida, T. Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy. PLoS ONE 12, e0184112. https://doi.org/10.1371/journal.pone.0184112 (2017).
doi: 10.1371/journal.pone.0184112
pubmed: 28850595
pmcid: 5574536
Sun, Z. et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy. Eye (Lond.) 34, 1592–1599 (2020).
doi: 10.1038/s41433-019-0692-8
Sacconi, R. et al. Response of central serous chorioretinopathy evaluated by multimodal retinal Imaging. Eye (Lond.) 32, 734–742 (2018).
doi: 10.1038/eye.2017.295
Cakir, B. et al. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 254, 2151–2157 (2016).
pubmed: 27145785
doi: 10.1007/s00417-016-3373-3
Daruich, A. et al. Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl. Vis. Sci. Technol. 5, 2 (2016).
pubmed: 26966638
pmcid: 4782825
doi: 10.1167/tvst.5.2.2
Bousquet, E. et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: A pilot study. Retina 33, 2096–2102 (2013).
pubmed: 23719402
doi: 10.1097/IAE.0b013e318297a07a
Toto, L. et al. Anatomical and functional changes of the retina and the choroid after resolved chronic CSCR. J. Clin. Med. 8, 474 (2019).
pmcid: 6517936
doi: 10.3390/jcm8040474
Scholz, P., Altay, L. & Fauser, S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond.) 30, 1371–1377 (2016).
doi: 10.1038/eye.2016.142
Breukink, M. B. et al. Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): Study protocol for a randomized controlled trial. Trials 16, 419 (2015).
pubmed: 26390920
pmcid: 4578347
doi: 10.1186/s13063-015-0939-z
Arora, S., Sridharan, P., Arora, T., Chhabra, M. & Ghosh, B. Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy. Clin. Exp. Optom. 102, 79–85 (2018).
pubmed: 30058731
doi: 10.1111/cxo.12818
van Rijssen, T. J. et al. Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy: The REPLACE trial. Am. J. Ophthalmol. 216, 80–89 (2020).
pubmed: 32289294
doi: 10.1016/j.ajo.2020.04.007
van Rijssen, T. J. et al. Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report no. 3. Am. J. Ophthalmol. 205, 1–10. https://doi.org/10.1016/j.ajo.2019.03.025 (2019).
doi: 10.1016/j.ajo.2019.03.025
pubmed: 30951686
Subhi, Y., Bjerager, J., Boon, C. J. F. & van Dijk, E. H. C. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data. Acta Ophthalmol. 100, 89–95 (2021).
pubmed: 33998168
doi: 10.1111/aos.14901
Ozmert, E., Demirel, S., Yanık, O. & Batıoğlu, F. Low-fluence photodynamic therapy versus subthreshold micropulse yellow wavelength laser in the treatment of chronic central serous chorioretinopathy. J. Ophthalmol. 2016, 3513794 (2016).
pubmed: 27597894
pmcid: 5002482
Koss, M. J., Beger, I. & Koch, F. H. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond.) 26, 307–314 (2012).
doi: 10.1038/eye.2011.282
Schwartz, R. et al. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 95, e610–e618 (2017).
pubmed: 28653813
doi: 10.1111/aos.13491
Guyer, D. R. et al. Digital indocyanine green angiography of central serous chorioretinopathy. Arch Ophthalmol. 112, 1057–1062 (1994).
pubmed: 8053819
doi: 10.1001/archopht.1994.01090200063023